Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14508619 | 0.89 | PARP1 (0.50) | KDM4EALDH1A1HSD17B10TP53HPGD | |
| SCHEMBL2815473 | 0.80 | ALDH1A1 (0.50) | KDM4EALDH1A1HSD17B10TP53HPGD | |
| SCHEMBL5754456 | 0.78 | CYP2D6 (0.53) | KDM4EALDH1A1GAACYP2D6CYP1A2 | |
| SCHEMBL14508634 | 0.78 | KMT2A (0.47) | KDM4EALDH1A1HSD17B10PARP1GAA | |
| SCHEMBL8265498 | 0.76 | CYP2C9 (0.59) | KDM4EALDH1A1HSD17B10HPGDGAA | |
| SCHEMBL537286 | 0.75 | CYP2C9 (0.54) | KDM4EALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL2483444 | 0.75 | PARP1 (0.89) | KDM4EALDH1A1HSD17B10TP53HPGD | |
| SCHEMBL5958253 | 0.75 | KDR (0.54) | KDM4EHSD17B10PARP1GAA | |
| SCHEMBL5957992 | 0.73 | RAB9A (0.52) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL14508638 | 0.73 | SMN1; SMN2 (0.48) | KDM4EALDH1A1HSD17B10HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | MKI67, VEGFA, FLT1 | KDM4E 4059/4885ALDH1A1 618/4885HSD17B10 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.